Johnson & Johnson said Tuesday that its Covid-19 vaccine helped lift overall sales in its most recent quarter, but the company is suspending its full-year guidance on sales of the shot, saying there is a global supply surplus and demand is uncertain.
The healthcare-products company sold $457 million of its Covid-19 vaccine in its most recent quarter, with international buyers accounting for most of those sales. In the same period a year earlier, shortly after the shot had been authorized in the U.S., the company’s Covid-19 vaccine sales were $100 million, exclusively in the U.S. In the previous quarter, the company’s global Covid-19 vaccine sales came in at $1.62 billion.
